Literature DB >> 11284803

Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers.

D Y Wang1, F Hanotte, C De Vos, P Clement.   

Abstract

BACKGROUND: Cetirizine, an effective H1-receptor antagonist, is a racemate mixture of two enantiomers: levocetirizine (R enantiomer) and dextrocetirizine (S enantiomer).
METHODS: To investigate the pharmacologic activity of the two enantiomers of cetirizine, we conducted a randomized, double-blind, four-way, crossover study to assess the effect of treatment with 5 mg levocetirizine, 5 mg dextrocetirizine, and 10 mg cetirizine and matched placebo, on histamine-induced changes in the nasal airways of 24 healthy volunteers. Four hours after a single oral intake, all subjects were challenged by nasal aerosol application with increasing doubling concentrations (from 0.25 to 32 mg/ml) of histamine in both nostrils. Nasal resistance was measured by passive anterior rhinomanometry (PAR), and changes in histamine threshold were calculated together with the absolute number of sneezes after each challenge.
RESULTS: Both levocetirizine and cetirizine significantly attenuated the histamine-induced increase in nasal airway resistance by nearly 50% (from a median resistance of 2.51 Pa per cm3/s to 1.29 and 1.31 Pa per cm3/s, respectively) at the maximal concentration, and they concomitantly increased the histamine threshold by fourfold (from 8 to 32 mg/ml), compared with placebo. Sneezing was also attenuated by both levocetirizine and cetirizine. However, these antihistaminic effects were not seen with dextrocetirizine.
CONCLUSIONS: This study shows a similar activity of levocetirizine and cetirizine on the inhibition of histamine-induced increase in nasal resistance, indicating that the antihistaminic properties of cetirizine are probably attributable to levocetirizine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11284803     DOI: 10.1034/j.1398-9995.2001.00775.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  13 in total

1.  Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial.

Authors:  Joris C Verster; A Marit de Weert; Saskia I R Bijtjes; Mounir Aarab; Armand W A A van Oosterwijck; Erik J E Eijken; Marinus N Verbaten; Edmund R Volkerts
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

Review 2.  The safety and efficacy of desloratadine for the management of allergic disease.

Authors:  William E Berger
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Chiral Switch Drugs for Asthma and Allergies: True Benefit or Marketing Hype.

Authors:  Kathryn Blake; Hengameh Raissy
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2013-09       Impact factor: 1.349

Review 4.  Sedative Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized Controlled Studies.

Authors:  Kornkiat Snidvongs; Kachorn Seresirikachorn; Likhit Khattiyawittayakun; Wirach Chitsuthipakorn
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

Review 5.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study.

Authors:  Ziad Hussein; Maria Pitsiu; Oneeb Majid; Leon Aarons; Marc de Longueville; Armel Stockis
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

7.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers.

Authors:  J M Gandon; H Allain
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

9.  Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study.

Authors:  Réginald Hulhoven; Dominique Rosillon; Michel Letiexhe; Marie-Anne Meeus; Agnès Daoust; Armel Stockis
Journal:  Eur J Clin Pharmacol       Date:  2007-09-21       Impact factor: 2.953

10.  Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin.

Authors:  Ashok Purohit; Michel Melac; Gabrielle Pauli; Nelly Frossard
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.